For research access and to learn how you can work with Alembic Global Advisors please email Stephen Matthews, stephen.matthews@alembicglobal.com.
Key Points We’re reiterating our Overweight rating on shares of CW after last Thursday’s 3Q24 earnings release and raising our target price by USD9 to USD421. We’ve maintained our 24x terminal...
Key Points Below-consensus Q3’24 EBITDA and EPS. Q4 guidance significantly below consensus on continued destocking Dividend temporarily cut and a series of earnings/cash generation improvement actions announced We have a Neutral rating on...
Key Points In line Q3’24 EPS but EBITDA beat; midpoint of Q4'24 guidance below consensus Pricing weakness observed across all segments (y-o-y) but volumes rose y-o-y in every segment; near-term commentary cautious We...
Key Points Q3’24 EBITDA and EPS beat Q4’24 guidance appears slightly below consensus; corporate strategy refreshed We rate CC shares Overweight, with a 12-month target price of USD27 per share Summary Chemours announced Q3’24 earnings...
Key Points We are reiterating our Overweight rating on shares of RBC after Friday’s 2QFY25 earnings release and we’re raising our target price by USD4 to USD337. Note our EPS projections...